Literature DB >> 2296585

Type II hereditary angioneurotic edema that may result from a single nucleotide change in the codon for alanine-436 in the C1 inhibitor gene.

N J Levy1, N Ramesh, M Cicardi, R A Harrison, A E Davis.   

Abstract

Identical single-base changes in the C1 inhibitor gene that may result in dysfunctional inhibitor proteins are described in two different families with type II hereditary angioneurotic edema. Initially, a restriction fragment length polymorphism was defined that resulted from loss of a Pst I site within exon VIII, which encodes the region containing the reactive center. Exon VIII from the normal and abnormal allelles was amplified by the polymerase chain reaction. Amplified DNA product was cloned into plasmid pUC18; clones representing normal and mutant allelles were distinguished by the presence and absence, respectively, of the Pst I restriction site. DNA sequence analysis revealed a G----A mutation in the codon for alanine-436, which would result in replacement with a threonine residue. This position is nine amino acid residues amino-terminal to the reactive-center arginylthreonine peptide bond. In contrast, previously defined mutations in type II hereditary angioneurotic edema result in replacement of the reactive-center arginine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2296585      PMCID: PMC53243          DOI: 10.1073/pnas.87.1.265

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Plasma serine proteinase inhibitors (serpins) exhibit major conformational changes and a large increase in conformational stability upon cleavage at their reactive sites.

Authors:  M Bruch; V Weiss; J Engel
Journal:  J Biol Chem       Date:  1988-11-15       Impact factor: 5.157

2.  Efficient transfer of large DNA fragments from agarose gels to diazobenzyloxymethyl-paper and rapid hybridization by using dextran sulfate.

Authors:  G M Wahl; M Stern; G R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

3.  Molecular basis of base substitution hotspots in Escherichia coli.

Authors:  C Coulondre; J H Miller; P J Farabaugh; W Gilbert
Journal:  Nature       Date:  1978-08-24       Impact factor: 49.962

4.  Interaction of plasma kallikrein with the C1 inhibitor.

Authors:  I Gigli; J W Mason; R W Colman; K F Austen
Journal:  J Immunol       Date:  1970-03       Impact factor: 5.422

5.  Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator.

Authors:  C D Forbes; J Pensky; O D Ratnoff
Journal:  J Lab Clin Med       Date:  1970-11

6.  Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.

Authors:  P C Harpel; N R Cooper
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

7.  Response of variant hereditary angioedema phenotypes to danazol therapy. Genetic implications.

Authors:  J E Gadek; S W Hosea; J A Gelfand; M M Frank
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

8.  Heat- and alkali-induced deamination of 5-methylcytosine and cytosine residues in DNA.

Authors:  R Y Wang; K C Kuo; C W Gehrke; L H Huang; M Ehrlich
Journal:  Biochim Biophys Acta       Date:  1982-06-30

9.  Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema.

Authors:  F S Rosen; C A Alper; J Pensky; M R Klemperer; V H Donaldson
Journal:  J Clin Invest       Date:  1971-10       Impact factor: 14.808

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  8 in total

1.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

2.  Dysfunctional C1 inhibitor Ta: deletion of Lys-251 results in acquisition of an N-glycosylation site.

Authors:  R B Parad; J Kramer; R C Strunk; F S Rosen; A E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

3.  C1 inhibitor functional deficiency in systemic lupus erythematosus (SLE).

Authors:  E C Jazwinska; P A Gatenby; H Dunckley; S W Serjeantson
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

4.  Nonsense mutations affect C1 inhibitor messenger RNA levels in patients with type I hereditary angioneurotic edema.

Authors:  D Frangi; M Cicardi; A Sica; F Colotta; A Agostoni; A E Davis
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

5.  C1-inhibitor gene nucleotide insertion causes type II hereditary angio-oedema.

Authors:  Z Siddique; A R McPhaden; K Whaley
Journal:  Hum Genet       Date:  1993-09       Impact factor: 4.132

6.  A mutation unique in serine protease inhibitors (serpins) identified in a family with type II hereditary angioneurotic edema.

Authors:  J G Ocejo-Vinyals; F Leyva-Cobián; J L Fernández-Luna
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

7.  Crucial residues in the carboxy-terminal end of C1 inhibitor revealed by pathogenic mutants impaired in secretion or function.

Authors:  E Verpy; E Couture-Tosi; E Eldering; M Lopez-Trascasa; P Späth; T Meo; M Tosi
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

8.  The murine Spi-2 proteinase inhibitor locus: a multigene family with a hypervariable reactive site domain.

Authors:  J D Inglis; R E Hill
Journal:  EMBO J       Date:  1991-02       Impact factor: 11.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.